pharmacovigilence

  1. D

    Disproportionality in Pharmacovigelence

    I am working on a project involving pharmacovigilance that was passed on to me by another individual. I am a little skeptical about the values used to calculate the proportional reporting ratio, so I would like your opinion on the method. First, the data is a matrix of m rows of adverse events...